The global endocrine testing market is currently valued at US$ 2536.7 Million and is anticipated to expand at a CAGR of 8.5%. With the rising prevalence of diabetes, and the rise in the geriatric population, the market is likely to propel to US$ 5735 Million by 2032.
Emerging endocrine disorders, self-testing pregnancy kits, and favorable government policies are likely to drive the growth of the endocrine testing market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2022) | US$ 2536.7 Million |
| Projected Forecast Value (2032) | US$ 5735 Million |
| Global Growth Rate (2022 to 2032) | 8.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider FMI, the endocrine testing industry grew at a CAGR of 8.3% from 2017 to 2021. Medical professionals use endocrine testing to diagnose endocrine disorders and treat the condition or disease accordingly. Innovating therapies, technologies, and advancing diagnostic methods will contribute to the market's growth.
New policies are being briefed for testing methods to detect endocrine disruptors. For example, EURION, a cluster of emerging ED research projects, published the research note. As part of EURION, eight research projects are collaborating to develop methods and determine test strategies for understudied disorders caused by EDs, such as metabolic, brain, thyroid, and reproductive problems. More than 70 research groups have partnered with the EC Horizon 2020-funded cluster since its launch in 2019, bringing over €50 million of funding and more than 50 years of experience together.
With the world returning to normalcy after the pandemic, self-test pregnancy kits are only set to become more popular. Moreover, advancements are being made in the development of endocrine testing devices that measure the level of hormones produced by the human body's endocrine glands.
Increased Defense Spending to Bolster Demand for Endocrine Testing
Medical and clinical diagnostic research and development (R&D), along with new technologies that are intended to improve patient outcomes, are among the factors driving the growth of endocrine testing worldwide. As consumers demand point-of-care facilities and home-based testing kits for a wide range of health-related issues, the market has grown substantially in the last few years.
As the prevalence of endocrine disorders continues to rise along with advances in diagnostic methods, the market will grow at a significant rate. In addition, the trend of an aging population worldwide, coupled with increased awareness about the importance of early diagnosis and prevention, will be expected to lead to the growth of this market. Tests to diagnose disorders like obesity, diabetes, and thyroid disease are carried out by measuring the level of hormones secreted by the endocrine glands.
WHO estimates that there are 650 million adults, 340 million adolescents, and 39 million children worldwide who are dealing with obesity, and this number is growing at an alarming rate. Overweight or obesity is predicted to affect the health of 167 million adults and children by 2025. Endocrine testing of thyroid function is more likely to be adopted as a result, resulting in further market growth for the product.
Technological advancement to drive the Endocrine Testing market growth during the forecast period.
Increasing the adoption of biosensors and digital test kits in pregnancy test kits and fertility test kits is expected to encourage the growth of the endocrine testing market.
During the testing, imbalances in hormone concentrations can be detected which can lead to chronic diseases. It is highly recommended to conduct periodic testing, particularly in elderly patients, in order to minimize the risk of developing complications or aggravating the disease. Investing in advanced endocrine testing techniques and diagnostic tests for the endocrine system will rise due to immunoassays remaining the most commonly used method to evaluate hormonal disorders. Also, investing in the integration of advanced endocrine testing techniques and diagnostic tests for endocrine systems will rise.
Principal Consultant
Stringent Regulations and the High Cost of Technologies May Impede the Growth of the Market
The high costs of developing and commercializing endocrine tests, including analyses of several hormone-stimulated cellular mechanisms, pose a challenge to manufacturers. Thus, it is inevitable that monitoring and diagnosing the secretion levels of hormones in the human body will result in a high cost to the patient.
However, because of the lack of qualified and skilled professionals in this field, the market growth is restricted due to narrow diagnostic capabilities. Endocrine function testing requires skilled as well as technical expertise due to sample handling and preparation stages. In the absence of a technical force that can perform endocrine testing with precision, the quality of the test will eventually be compromised, resulting in poor patient outcomes.
Endocrine testing solutions and methodologies are developed and introduced successfully because of improved access to sophisticated technological platforms. Government regulations restricting the development of diagnostic tests for endocrine systems and approval before they can be sold would raise costs, limiting the market growth. Because of this limitation, it deprived patients of being able to access advanced diagnostic procedures in order to receive quality diagnostic measures and decrease their chances of improving their quality of life. Consequently, high costs associated with testing technology could hamper the growth of the endocrine testing market.
Research & Development Investments and Diagnostic Advancements in the Region Provide Growth Opportunities
As the top market for endocrine testing, North America is expected to show a CAGR of 47.2% through the forecast period. A significant increase in Research and Development investments has encouraged the development of new products for endocrinology lab tests, which is expected to augment the growth of the North American endocrinology lab tests market in the coming years.
The adoption of new technologies and the continued reform of endocrine testing projects in numerous countries are expected to boost endocrine testing in the region over the forecast period.
Additionally, major manufacturers' Research and Development programs and technological advances in the USA and Canada resulted in major advancements.
A growing number of thyroid cases are being diagnosed globally throughout the world, and the rising prevalence of obesity is driving the global endocrine testing market. Approximately 43,800 new cases of thyroid cancer are expected to be detected in the United States in 2022 (11,860 in men and 31,940 in women) and there will be 2,230 thyroid cancer deaths (1,070 men and 1,160 women). Since thyroid cancer is common and causes many deaths in the United States, this will drive the market demand for thyroid testing in the United States.
Governing Policies and Reimbursements in Europe to Boost the Market Growth.
In 2022, Europe is predicted to lead the endocrine testing market and will continue to do so throughout the forecast period. At present, the endocrine testing market in Europe represents 33.6% of the global market share of the endocrine testing market.
Several key factors contributing to the dominance of endocrine testing include the high prevalence of chronic endocrine disorders and reproductive health problems. The United Kingdom, Germany, France, and Russia are expected to increase the procurement of advanced technologies, thus boosting the market.
In the United Kingdom, the reimbursement scheme is the most progressive and facilitates the rapid adoption of novel testing technologies. This allows Europe to dominate the market owing to supportive government regulations. Key market players have continued to invest in infrastructure development initiatives that are predicted to fuel global demand for endocrine testing.
Future Growth Scope Will be Broadened by Growing Demand for Pregnancy Test Kits and Infrastructure Growth
Asia Pacific was the largest market for endocrine testing with a revenue share of 35.6% and is expected to be the largest market going forward. There are several countries that are making significant investments in home-based endocrine testing kits, including China, India, Japan, and South Korea. With the growing population base, the increasing prevalence of lifestyle-related diseases, and the development of hormonal stimulation drugs, the market is likely to continue to experience growth in the coming years.
Endocrine testing has grown in popularity with the increasing number of thyroid disorders and diabetes being diagnosed in older as well as younger generations, which has contributed to the market growth. Moreover, the government has also taken measures in the region to improve the health infrastructure and provide access to quality healthcare, which are both driving the market growth in this region.
The growth and upgrading of self-test pregnancy kits and fertility test kits in this region are expected to drive the growth of the endocrine testing market in this region. Furthermore, the growth of the market for digital pregnancy test kits will further contribute to the growth of the market in the future.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| United Kingdom | 20.3 % |
|---|---|
| India | 22.5% |
| South Korea | 16.4 % |
| China | 19.9 % |
| USA | 26.4 % |
Immunoassay Technology Segment Generates High Revenue in the Endocrine Testing market
Based on technology immunoassay segment is projected to account for a CAGR of 18.2% in 2032. The market is expected to grow due to the increasing efficacy of antibody tests which are expected to drive market growth in the near future.
Due to the fact that there are multiple instruments and analyzers that are used for testing in order to detect the test result, different types of immunoassay technologies are utilized for the test. Moreover, there are many key players that offer immunoassay-based test panels for endocrine function and reproductive function along with many other products that contribute to the largest revenue generation in this market.
Technological advancements have led to the development of novel hormone testing methods in recent years. Nucleic acid-based detection methods, mass spectroscopy, and chromatography are becoming more widely used for endocrine testing panels and providing accurate results in a shorter time frame. All these factors will further propel market growth for the immunoassay endocrine testing market.
The Hospital segment is expected to grow at a high CAGR during the forecast period
In 2022, the hospital segment accounted for the largest share of 53 % and is expected to continue this trend over the forecast period. With increasing investments in healthcare infrastructure, particularly research activities, endocrine testing should see a positive impact globally.
At-home collection services and the availability of a variety of home-based test, panels are boosting the revenue generation of this segment. As a matter of fact, it is expected that hospitals will also experience the fastest growth in the following years. As health consciousness increases among individuals and endocrine testing are carried out continuously to monitor existing diseases and control hereditary conditions, this is a risk factor that can be attributed to the rise in health consciousness. Moreover, the ability to provide reports to the hospital settings over digital platforms further contributes to the growth trajectory of these hospital settings.
How do New Entrants Contribute to the Endocrine Testing Business?
Startups are now entering the endocrine testing market, providing consumers with new products that meet their needs. Additionally, these innovative testing companies offer different kinds of endocrine testing equipment and methods, including the technologies that are used during the testing process. Several start-up companies are now focusing on the preparation of FDA-approved endocrine tests due to the popularity of FDA-approved products on the market.
Through strategic partnerships, manufacturers can boost revenues and gain a greater share of the market by increasing production and meeting consumer demand. As a result of endocrine testing, the end user will benefit by taking advantage of new products and technologies. Expanding production capabilities can be achieved through strategic partnerships.
Key players in the global endocrine testing market include Abbott Laboratories, AB Sciex, Agilent Technologies Inc., bioMerieux SA, Bio-Rad Laboratories, DiaSorin S.p.A., F.Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Ortho Clinical Diagnostics.
| Report Attribute | Details |
|---|---|
| Growth Rate (2022 to 2032) | 8.5% |
| Expected Market Value (2022) | US$ 2536.7 Million |
| Projected Forecast Value (2032) | US$ 5735 Million |
| Base Year for Estimation | 2021 |
| Historical Data | 2018 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The global endocrine testing market is likely to reach a valuation of US$2536.7 million by the end of 2022.
Abbott Laboratories, Agilent Technologies Inc., AB Sciex, bioMerieux SA, DiaSorin S.p.A., Bio-Rad Laboratories, F.Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Ortho Clinical Diagnostics and Laboratory Corporation of America Holdings.
Sales of the endocrine testing market are likely to expand at 8.5% CAGR through 2032.
The USA, Canada, India, China, and Germany are predicted to drive most of the endocrine testing market demand.
By the end of 2032, the global market for the endocrine testing market is predicted to reach a valuation of US$ 5735 Million
1. Executive Summary | Endocrine Testing Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Test Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2022 to 2032
5.3.1. Estradiol (E2) Test
5.3.2. Follicle Stimulating Hormone (FSH) Test
5.3.3. Human Chorionic Gonadotropin (hCG) Hormone Test
5.3.4. Luteinizing Hormone (LH) Test
5.3.5. Dehydroepiandrosterone Sulfate (DHEAS) Test
5.3.6. Progesterone Test
5.3.7. Testosterone Test
5.3.8. Thyroid Stimulating Hormone (TSH) Test
5.3.9. Prolactin Test
5.3.10. Cortisol Test
5.3.11. Insulin Test
5.3.12. Others
5.4. Y-o-Y Growth Trend Analysis By Test Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Test Type, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Technology
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2022 to 2032
6.3.1. Mass Spectroscopy
6.3.2. Immunoassay
6.3.3. Chromatography
6.3.4. Nucleic Acid Based
6.4. Y-o-Y Growth Trend Analysis By Technology, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Technology, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End-user
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2022 to 2032
7.3.1. Hospitals
7.3.2. Commercial Laboratories
7.3.3. Ambulatory Care Centers
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End-user, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By End-user, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East and Africa(MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Test Type
9.2.3. By Technology
9.2.4. By End-user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Test Type
9.3.3. By Technology
9.3.4. By End-user
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Test Type
10.2.3. By Technology
10.2.4. By End-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Test Type
10.3.3. By Technology
10.3.4. By End-user
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Test Type
11.2.3. By Technology
11.2.4. By End-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Test Type
11.3.3. By Technology
11.3.4. By End-user
11.4. Key Takeaways
12. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Test Type
12.2.3. By Technology
12.2.4. By End-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Test Type
12.3.3. By Technology
12.3.4. By End-user
12.4. Key Takeaways
13. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Test Type
13.2.3. By Technology
13.2.4. By End-user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Test Type
13.3.3. By Technology
13.3.4. By End-user
13.4. Key Takeaways
14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Test Type
14.2.3. By Technology
14.2.4. By End-user
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Test Type
14.3.3. By Technology
14.3.4. By End-user
14.4. Key Takeaways
15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa(MEA)
15.2.2. By Test Type
15.2.3. By Technology
15.2.4. By End-user
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Test Type
15.3.3. By Technology
15.3.4. By End-user
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2021
16.1.2.1. By Test Type
16.1.2.2. By Technology
16.1.2.3. By End-user
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2021
16.2.2.1. By Test Type
16.2.2.2. By Technology
16.2.2.3. By End-user
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2021
16.3.2.1. By Test Type
16.3.2.2. By Technology
16.3.2.3. By End-user
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2021
16.4.2.1. By Test Type
16.4.2.2. By Technology
16.4.2.3. By End-user
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2021
16.5.2.1. By Test Type
16.5.2.2. By Technology
16.5.2.3. By End-user
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2021
16.6.2.1. By Test Type
16.6.2.2. By Technology
16.6.2.3. By End-user
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2021
16.7.2.1. By Test Type
16.7.2.2. By Technology
16.7.2.3. By End-user
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2021
16.8.2.1. By Test Type
16.8.2.2. By Technology
16.8.2.3. By End-user
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2021
16.9.2.1. By Test Type
16.9.2.2. By Technology
16.9.2.3. By End-user
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2021
16.10.2.1. By Test Type
16.10.2.2. By Technology
16.10.2.3. By End-user
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2021
16.11.2.1. By Test Type
16.11.2.2. By Technology
16.11.2.3. By End-user
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2021
16.12.2.1. By Test Type
16.12.2.2. By Technology
16.12.2.3. By End-user
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2021
16.13.2.1. By Test Type
16.13.2.2. By Technology
16.13.2.3. By End-user
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2021
16.14.2.1. By Test Type
16.14.2.2. By Technology
16.14.2.3. By End-user
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2021
16.15.2.1. By Test Type
16.15.2.2. By Technology
16.15.2.3. By End-user
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2021
16.16.2.1. By Test Type
16.16.2.2. By Technology
16.16.2.3. By End-user
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2021
16.17.2.1. By Test Type
16.17.2.2. By Technology
16.17.2.3. By End-user
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2021
16.18.2.1. By Test Type
16.18.2.2. By Technology
16.18.2.3. By End-user
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2021
16.19.2.1. By Test Type
16.19.2.2. By Technology
16.19.2.3. By End-user
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2021
16.20.2.1. By Test Type
16.20.2.2. By Technology
16.20.2.3. By End-user
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2021
16.21.2.1. By Test Type
16.21.2.2. By Technology
16.21.2.3. By End-user
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Test Type
17.3.3. By Technology
17.3.4. By End-user
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Abbott Laboratories
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. AB Sciex
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Agilent Technologies Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. bioMerieux SA
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Bio-Rad Laboratories Inc.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. DiaSorin S.p.A.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. F. Hoffmann-La Roche Ltd.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Laboratory Corporation of America Holdings
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Quest Diagnostics Incorporated
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Ortho Clinical Diagnostics
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Endocrine Testing Market
